Immuron has cows and ferrets fighting swine flu
05 May, 2010 by Tim DeanAntibody specialists, Immuron, are on the cusp of beginning pre-clinical trials of its Influenza prevention antibody treatment after receiving the go ahead from the CSIRO animal ethics committee.
BIO 2010: Biotech enters 'new normal' phase
04 May, 2010 by Tim DeanThe worst of the global financial crisis has passed, but the biotech industry isn't returning to business as usual.
BIO 2010: Australian biotech, state of the nation
04 May, 2010 by Tim DeanIt’s not just the Big Three – CSL,ResMed and Cochlear – with high hopes for 2010. Many other Australian biotechnology companies are either in the final stages of trials and are close to gaining regulatory approval, or they are in the initial stages of commercialising their products, with several forming strategic partnerships to expand into new and lucrative overseas markets.
BIO 2010: Diagnosis positive for ImpediMed
03 May, 2010 by David BinningIn March this year the American Medical Association (AMA) assigned the all important Category III coding to ImpediMed’s bio-impedance spectroscopy (BIS) technology, enabling physicians to be reimbursed for its use in the early detection of lymphedema.
BIO 2010: QRxPharma begins end run
30 April, 2010 by Tim DeanSometimes the whole is greater than the sum of its parts. That’s certainly the case with pharmaceutical company, QRxPharma. Not only does its lead product, MoxDuo, combine two existing drugs to give a superior effect with fewer side effects than current products, but the company has combined a strong background in science with a prudent approach to clinical trials to build a robust biotechnology company with global aspirations.
BIO 2010: Kim Carr on biotech in 2010
30 April, 2010 by Kim CarrTwo thousand and nine was an extraordinary year. When I last wrote twelve months ago, we were in the thick of a global economic crisis. The biotechnology industry, like most Australian industries, was feeling the effect of the downturn. Thanks to swift action by the Commonwealth, Australia has fared better than just about any other developed nation.
US healthcare bill already impacting biotechs
29 April, 2010 by Tim DeanAccording to an analyst at Datamonitor, it's a bumpy road ahead for the life sciences and pharmaceutical industry in the United States as a result of the recently passed healthcare bill along with the 'patent cliff' due to arrive around 2011.
BioProspect keeps the termites at bay
23 April, 2010 by Tim DeanTermites hate it, but home owners may come to love it. It's the termite repellent developed by Australian natural products developer, BioProspect.
BIO 2010: Biotechs ready themselves for recovery
22 April, 2010 by Tim DeanIf you excuse the mixed metaphor, there is light at the end of the tunnel, but we’re not out of the woods yet. That appears to be the sentiment amongst the Australian biotechnology community in the opening months of 2010.
Xenome rustles up another $10 million
22 April, 2010 by Tim DeanQueensland-based private biopharma company, Xenome, has raised $10 million in funds in the form of convertible notes to fuel continued development of its flagship pain drug, Xen2174.
Biotech sector continues strong recovery: PwC
21 April, 2010 by Tim DeanThe biotechnology sector has seen another quarter of strong growth, with the majors - CSL, ResMed and Cochlear - putting in healthy performances, according to PricewaterhouseCoopers' latest BioForum report.
BIO 2010: Queensland fields strong delegation
20 April, 2010 by Staff WritersThe Australian biotechnology industry is warming up for BIO 2010, to be held in Chicago from May 3-6, and Queensland is planning on being well represented at the world's largest biotech convention.
Market Spotlight: LBT Innovations makes bonus $500K from currency hedging
19 April, 2010 by Tim DeanLBT Innovations received two bits of good news today. First is that €2 million came through as a scheduled milestone payment from bioMérieux for LBT's MicroStreak technology.
Australian biotech market watch 16/04/10
16 April, 2010 by Tim DeanThe All Ordinaries dipped back towards the 5,000 mark after seeing well over a month of consistent gains, including pipping 5,000 for the first time since the onset of the global financial crisis.
Market Spotlight: QRxPharma on the up
14 April, 2010 by Tim DeanQRxPharma is another step closer to bringing its immediate release dual-opioid pain therapy, MoxDuoIR, to the market with the completion of one of two pivotal Phase III clinical trials held in the United States.
